Registration is open for SMi’s 2nd Annual Next Generation Pharmaceutical Cleanroom

SMi Reports: Registration is now open for the 2nd Annual Next Generation Pharmaceutical Cleanroom Conference will convene in London on 6-7tOctober 2021

LONDON, GREATER LONDON, UNITED KINGDOM, May 31, 2021 / — Following on from the success of the inaugural conference, SMi Group Next Generation Pharmaceutical Cleanroom, returning in London, UK on the 6th and 7th October 2021.

Chaired by Matts Ramstorp, CEO & Founder, BioTekPro AB, this conference will explore the latest schools of thought in the cleanroom industry, from operator management and environmental monitoring to breakthroughs in the future of cleanroom design and Contamination Control Strategy.

Interested parties can register by 30th June 2021 and save £200 at

SMi’s 2nd Annual Next Generation Pharmaceutical Cleanroom Conference will feature a much-anticipated speaker line-up, including:

Keynote Speaker & Panel Moderator:
• Tim Sandle, Bio Banking Operations, Bio Products Laboratory

Featured Expert Speakers Include:
• Stephen Ward, General Secretary, Contamination Control Network
• Conor Murray, Principal, Irish Cleanroom Society
• Dawn Tavalsky, Senior Director Global Sterility Assurance, Sanofi Pasteur
• Dawn Watson, Director – Microbial Control, Sterile & Validation Center of Excellence, MSD
• Benoit Ramond, Head of Microbiology and Sterile Technology, Sanofi
• Fred Ohsiek, Senior Specialist, Cleaning Validation, Novo Nordisk
• Patrizia Muscas, Sterility Assurance Senior Research Scientist Global, Eli Lilly

Featured Commercial Speakers:
• Sebastian Scheler, Lead Psychologist and Co-Founder, Innerspace GMBH
• Helen Gates, Global Technical Consultant, ECOLAB
• Richard Denk, Senior Consultant Aseptic Processing & Containment, SKAN AG
• Beth Kroeger-Fahnestock, Technical Services, STERIS Corporation
• Walid El Azab, Senior Manager Technical Service, STERIS Corporation
Plus many more….

Key topics that will be covered at the conference include: :
• Gain insight into the revised regulations and new standards, from EN 17141 to EU Annex 1 GMP
• Examine the changes to Annex 1 and strategies of Environmental Monitoring Program implementation with Sanofi and Merck
• Explore the challenges of creating cleanrooms fit for purpose and qualifying automated filling lines
• Uncover the effective risk-based approaches in cleanroom verification and cleaning monitoring
• Discuss the advantages of robotics in cleanrooms and the automated cleanroom of the future
• Join the in-depth panel on the latest regulatory standards and the impact of the pandemic on the industry

This year’s conference will have two interactive pre-conference workshops on 5th October. These will focus on ‘Applying ISO and EN Standards to Non-Viable and Viable EM in the context of the New Annex 1 Guidance and a CCS in GMP Cleanrooms’ and ‘Cleanroom Garments – Need, Function and Use.’

The full speaker line-up, agenda and brochure is available at

The conference is sponsored by: Ecolab, Elis Cleanroom & Innerspace
For sponsorship enquiries contact Alia Malick on +44 (0)20 7827 6164 or

For media enquiries, contact Simi Sapal on +44 (0) 20 7827 6162 or


SMi’s 2nd Annual Next Generation Pharmaceutical Cleanroom
Conference: 6 – 7 October 2021
Interactive Workshops: 5 October 2021
London, UK

About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at

Simi Sapal
SMi Group
+44 20 7827 6000
email us here

Source: EIN Presswire

IVI to develop an adaptive Phase 1b/2a schistosomiasis vaccine clinical trial

SEOUL, REPUBLIC OF KOREA, May 31, 2021 / — The International Vaccine Institute (IVI) announced today that the Bill & Melinda Gates Foundation awarded a grant to IVI to develop an adaptive trial design protocol for a Phase 1b/2a clinical trial of a schistosomiasis vaccine.

The grant is a Trial Planning Grant, part of the Gates Foundation’s Design, Analyze, Communicate (DAC) program which supports grantees in optimizing clinical studies for informativeness and impact. The goal of IVI’s schistosomiasis vaccine project is to advance the development of a safe, effective, and affordable vaccine to reduce morbidity and mortality from schistosomiasis in moderate- to high-transmission settings.

Dr. Florian Marks, Deputy Director General of Epidemiology, Public Health, and Impact at IVI, said: “A safe, effective, and accessible vaccine is the most sustainable solution to breaking the devastating cycle of Schistosomiasis infection and will save lives and improve the livelihoods of hundreds of millions of people. We are grateful to the Gates Foundation for their support and guidance in planning an adaptive Phase 1b/2a clinical trial for a schistosomiasis vaccine candidate which would accelerate the clinical development timeline as well as licensure and pre-qualification processes.”

Dr. Thea Norman, PhD, leader of the Design, Analyze, Communicate program, said: “IVI is an exemplar of the type of partner that DAC Program looks for. IVI was an early adopter of our trial planning grants, is operating out in the field in low-resource settings, and now adds an approach to answer more questions during a trial.”

IVI’s schistosomiasis vaccine project has successfully sourced funding from the National Institute of Allergy and Infectious Diseases (NIH) and EU Horizon 2020 to support Phase 1 clinical trials of the SchistoShield vaccine. These trials include a first-in-human safety study in healthy American adults at an NIH Vaccine and Treatment Evaluation Unit followed by a Phase 1b safety and immunogenicity placebo-controlled study in healthy adults in Burkina Faso and Madagascar. With this Trial Planning Grant from the Gates Foundation, the IVI team will be able to adapt the Phase 1b study design, that could help speed up clinical development of the vaccine.

Dr. Tarun Saluja, Research Scientist at IVI, said: “With the IVI team’s experience in designing adaptive trial designs for various vaccine candidates, we are looking forward to this opportunity to develop a comprehensive, responsive, and efficient protocol to advance a critically needed schistosomiasis vaccine while ensuring the highest standards for patient safety and data integrity.”

About Schistosomiasis
Schistosomiasis is a parasitic disease caused by trematode worms of the genus Schistosoma and is the cause of significant morbidity for an estimated 200 million people, with an additional 779 million individuals at risk for infection with the highest burden in sub-Saharan Africa. The only currently available treatment is praziquantel (PZQ), which is effective against all Schistosoma species; however, PZQ treatment does not prevent re-infection and mass drug administration programs have shown sub-optimal outcomes and low sustainability.

About SchistoShield
SchistoShield® (Sm-p80 adjuvanted in GLA-SE) is an anti-schistosomal vaccine candidate that has shown a satisfactory safety and good efficacy profile in non-human primate studies. The candidate exhibits multiple mechanisms of action in the Schistosome life cycle and thus could potentially prove a valuable tool to break the cycle of schistosomiasis infection.

About the International Vaccine Institute (IVI)
The International Vaccine Institute (IVI) is a nonprofit inter-governmental organization established in 1997 at the initiative of the United Nations Development Programme (UNDP). IVI has 36 signatory countries and the World Health Organization (WHO) on its treaty, including Korea, Sweden, India, and Finland as state funders.

Our mandate is to make vaccines available and accessible for the world’s most vulnerable people. We focus on infectious diseases of global health importance such as cholera, typhoid, shigella, salmonella, schistosomiasis, chikungunya, Group A Strep, Hepatitis A, HPV, TB, HIV, MERS, COVID-19, as well as antimicrobial resistance. For more information, please visit

Aerie Em
International Vaccine Institute
Visit us on social media:

Source: EIN Presswire

Buddies Bites Release New Dog Treat For Dogs with Anxiety

Buddies Bites has released an all natural dog treat for dogs anxiety.

ADEL, IOWA, UNITED STATES, May 30, 2021 / — Dogs can experience anxiety for several reasons. From stress caused by fireworks to a full-blown case of separation anxiety, there are plenty of ways that a dog's nerves can get on edge. When that happens it can cause a lot of trauma for both the dog with anxiety and the dog owner.

The aim of Buddies Bites is to help dog owners quickly and easily treat this anxiety.

Separation stress, also called separation anxiety, is a term applied to a variety of behaviors that can occur when a dog is left alone. The severity of separation stress and behaviors associated with this issue vary among dogs. Common symptoms of separation anxiety in dogs include clinginess, pacing, panting, whining, barking or howling inability to settle, hovering near doors, house-soiling (accidents). In severe cases, dogs may become destructive, hurt themselves or attempt to escape.

Many dogs that in the past never exhibited any type of anxiety issues are now experiencing it for the first time due to Covid. Most businesses required their employees to work from home as covid spread throughout the country. Their dogs then became used to their owners being home with them all of the time. Now these pet owners are returning to work and the dogs are obviously not used to this since them have been with them for the past 14 months.

Buddies Bites can help solve this issue. The all natural dog treats are made with just 7, non-gmo ingredients and have been shown to reduce anxiety in less than 26 minutes. Since they were formulated to be great tasting they are extremely convenient and easy to give to your dog.

Veterinarians are also recommending Buddies Bites to their patients because they also treat and prevent both hip and joint pain.

With the “Love Every Bite” Guarantee, dog owners can try these amazing dog treats virtually risk free. The immediate refund will be issued immediately for their guaranteed satisfaction.

Buddies Bites are great tasting dog treats that will help get the anxiety in your dog under control in less than 27 minutes.

Buddies Bites are all natural and made with just 7 all natural ingredients and are manufactured in the United States.

Steve Recardo
Buddies Bites
+1 800-597-8847

Source: EIN Presswire

Cost of Savannah River Site Plutonium Bomb Plant Soars to $11 Billion; DOE's Nuclear Bomb Facility Jolts FY22 Funding

Diagram of nuclear warhead with plutonium pit

Though plutonium pits have a 100+-year lifespan, proponents of new pits for new nuclear weapons have proposed the unneeded, $11-billion SRS Plutonium Bomb Plant to make pits for old and new nuclear weapons, starting with pits for the W87-1 Warhead for the new GBSD ICBM

Terminated plutonium fuel (MOX) plant at DOE's Savannah River Site

Partially finished Mixed Oxide Fuel Fabrication Facility (MFFF) at DOE’s Savannah River Site in South Carolina; Boosters want to convert the MOX plant to the SRS Plutonium Bomb Plant (PBP) – photo by High Flyer

SRS Watch logo

SRS Watch, Columbia, SC, is a non-profit organization working on sound policies and projects by the U.S. Department of Energy at SRS. We oppose the new nuclear arms race new nuclear weapons and new pits would spur and support international negotiation for disarmament.

NNSA Request of $475 Million for Unneeded Pit Production Plant for Nuclear Warheads is Far Under Annual Level Needed for Controversial Project, Spells Trouble

DOE's plans to throw vast sums of money at the provocative Plutonium Bomb Plant fits the classic DOE formula for technical and financial failure. Congress should defund and terminate the project.”

— Tom Clements, Director, SRS Watch

COLUMBIA, SC, US, May 29, 2021 / — The U.S. Department of Energy budget request to Congress for Fiscal Year 2022 holds some startling surprises related to fabrication of plutonium “pits” for nuclear warheads at the DOE’s Savannah River Site in South Carolina. The biggest shock in the budget request by DOE’s National Nuclear Security Administration is that the total estimated cost of the SRS pit plant has soared to $11.1 billion, more than double the previous cost estimate of $4.6 billion (in the FY 21 budget request).

Thus, in a one-week period, the cost estimate of the SRS Plutonium Bomb Plant (PBP) has more than doubled in cost and the schedule for the facility’s initial operation has slipped up to five years. These troubling and potentially debilitating developments foreshadow problems to come to the challenging pit-production project, according to the public interest group Savannah River Site Watch.

The breath-taking $11.1 billion cost comes weeks before a key decision will be made on the planning for the facility, so-called “Critical-Decision-1.” That decision point will include a cost range for the PBP and the budget states that the $11.1 billion “value does not represent the CD-1 approved high end of the range.” (pages 220 and 225) Thus, an even higher figure can be expected to be reported in mid-June. DOE claims that better cost estimates will come with “CD-2/3 approval in FY23-24.” (page 211)

Given DOE’s extremely poor track record in managing complex and costly construction projects, as was seen with the MOX debacle, it is fully expected that the pit plant cost will increase over time and that the schedule for the project will continue to slip. The high cost of the SRS pit plant construction and operation will put extreme pressure on both the pit project and the new W87-1 nuclear warhead – atop the new, proposed Ground Based Strategic Deterrent missile – for which the first pits would be made, according to SRS Watch.

Though pressure is growing on the unneeded GBSD, DOE and DOD have so far refused to reassess the supposed need for the costly weapons system and the need for new plutonium pits on its warhead. Over 15,000 pits are in storage at DOE’s Pantex site in Texas and experts have stated that they “have credible minimum lifetimes in excess of 100 years as regards aging of plutonium.” (JASON “Pit Lifetime” report to NNSA, January 2007)

The DOE budget request includes $603 million for “Savannah River Plutonium Modernization,” with $475 million of that being for conversion of the partially constructed plutonium fuel (MOX) plant into the SRS Plutonium Bomb Plant, which DOE calls the Savannah River Plutonium Processing Facility. (page 171) The pit plant would receive $233 million more than it did in FY22. Yet these funding levels are far below what DOE admits it annually needs.

According to the budget request, if $475 million is approved for Fiscal Year 2022 spending on the SRS pit plant, $9.6 billion will be left to go to reach the $11.1 billion cost of the PBP. (page 220) This means that around $800-900 million per year will be needed for the construction project alone. “The incredible sums of money that DOE claims that it annually needs over the next decade for SRS pit-plant construction and support activities reveal the fragility of the project and that it could fail due to cost reasons alone,” said Clements of SRS Watch. The FY22 budget request falls far short of the needed annual spending and DOE has not explained how much larger funding amounts will be obtained. “Given challenges in converting the MOX plant to pit production and the technical hurdles in making pits, a mission never undertaken by SRS, could also lead to project failure,” added Clements.

The budget request confirms a delay in the SRS pit plant from the stated goal of it producing 50 pits per year by 2030. The documents states that “achieving the required 50 war reserve ppy production rate at the Savannah River Site in 2030 is not likely.” (page 211) During testimony before the Senate Armed Service Committee on May 26, 2021, Jill Hruby, the nominee to be the NNSA administration revealed that the project that had slipped from 2030 to between 2030 and 2035. (See archived SASC hearing link, with Hruby comments at 55 minutes.) That delay will only increase cost pressure on the project, according to SRS Watch.

“Plans to throw vast sums of our money at an unjustified, rushed Plutonium Bomb Plant, central to a new nuclear arms race, is a DOE formula for failure and, like the mismanaged MOX project, is guaranteed to run far over budget and fall far behind schedule,” according to Tom Clements, director of SRS Watch. “Congress should reject the extravagant spending levels that DOE is proposing for production of plutonium pits and stop consideration of SRS for this dangerous and costly mission,” added Clements. “Production of 80 pits per year at Los Alamos and Savannah River should be halted and efforts put into increasing national security by entering into international nuclear weapons disarmament negotiations,” said Clements.

The release of the DOE budget was badly bungled, with the NNSA budget volume not being released until around 7 p.m. on Friday, May 28. Due to this embarrassing stumble, reports and members of the public were left hanging as to how DOE was proposing to spend tax payer funds. Key budget documents for DOE’s environmental clean-up and nuclear energy programs had inexplicably not been posted by mid-day Saturday, May 29.

The South Carolina Environmental Law Project (SCELP) is representing SRS Watch, Nuclear Watch New Mexico and Tri-Valley CAREs in a possible lawsuit in late June against DOE for not meeting the NEPA environmental law in planning for plutonium pit-production expansion. See SCELP’s “pit page,” including April 21, 2021 news release and letter to DOE.


On SRS Watch website (, see full news release:

Tom Clements
Savannah River Site Watch
+1 803-834-3084
email us here
Visit us on social media:

Source: EIN Presswire


The two-minute version of the “Dear Earth” video for clean energy from space. Credit: Rod Pyle

The 42nd Annual Telly Awards. Credit: The Telly Awards

Video Spots Explain the Benefits of Clean and Unlimited Space-Based Solar Power to Our Planet

We’re thrilled to have won this award and hope to continue to spread the word about the importance of the National Space Society’s work towards a better life for everyone on our planet.”

— Rod Pyle, Editor-in-Chief, Ad Astra Magazine

WASHINGTON, D.C., USA, May 28, 2021 / — The National Space Society announced today its “Dear Earth” campaign for space solar power has been named in the Best of Social Media category in the 42nd Annual Telly Awards. The Telly Awards honor excellence in video and television across all venues and are judged by industry leaders from broadcast television, streaming networks, top production companies and other venues, including Netflix, Dow Jones, Complex Networks, A&E Networks, Hearst Media, Nickelodeon, ESPN Films, RYOT, Partizan and Vimeo.

The “Dear Earth” campaign, voiced by Samantha Clark, highlights the ways in which solar power generated in orbit and beamed to Earth can provide limitless, clean energy that will be affordable and drastically lessen our dependence on fossil fuels. In contrast to ground-based solar panels, orbital power stations can operate 24 hours per day all year long.

“This campaign is part of a series of video presentations the National Space Society is creating about the benefits of developing space,” said Rod Pyle, the producer/director of the spots and Editor-in-Chief of the society’s quarterly print magazine, Ad Astra. “We’re thrilled to have won this award and hope to continue to spread the word about the importance of the NSS’s work.”

Anita Gale, the CEO of the NSS, added, “We at the NSS feel it is very important to bring the broader public into what has long been an insufficiently publicized conversation—the importance of space to everyone on Earth. This is not just about exploring planets with robots and sending astronauts to the Moon—this aspect of space development will go a long way toward restoring our own planet’s environment and reducing the impact of greenhouse gasses on our atmosphere.”

Last year, The Telly Awards attracted more than 12,000 entries from top video content producers including Adobe, Adult Swim, the BBC, Condé Nast, J. Paul Getty Museum, PBS, Playstation, RadicalMedia, T Brand Studio, Ogilvy & Mather and The Walt Disney Company. The full list of the 42nd Annual Telly Awards winners can be found at

The National Space Society was founded in 1987 via a merger of the National Space Institute, founded to promote citizen support for the American space program, and the L5 Society, based on the work of space settlement pioneer Gerard K. O’Neill. The NSS is the preeminent citizen's voice on space exploration, development, and settlement. For more information go to

Rod Pyle
National Space Society
+1 626-399-4440
email us here
Visit us on social media:

Source: EIN Presswire

Key updates ahead of SMi’s 4th Annual Pharmaceutical Microbiology West Coast Virtual Conference in three weeks!

SMi Group Reports: Key updates released ahead of SMi’s 4th Annual Pharmaceutical Microbiology West Coast Conference, convening in just three weeks.

SAN DIEGO , CA, UNITED STATES, May 28, 2021 / — SMi Group are delighted to announce that the 4th Annual Pharmaceutical Microbiology West Coast Conference, will take place on June 17th and 18th 2021. With only three weeks remaining, the pharmaceutical microbiology industry will be gathering to explore novel approaches and best practices for tackling current industry contamination control challenges.

SMi Group are also proud to announce that the two-day agenda will feature several highly anticipated presentations and that several key updates have been added to the ‘download centre’ of the conference website.

Interested parties can register now at US$499 for pharmaceutical and biotechnology firms and US$999 for vendors and commercial firms at

The 4th Annual Pharmaceutical Microbiology West Coast Conference will include an esteemed agenda including several key spotlight sessions:

• ‘Objectionable Organisms in Non-Sterile Drug Products – Guidance, Regulations, and Case Studies’
Presented by Stephen Langille, Senior Microbiology Consultant, ValSource
• ‘Changing the Paradigm: Moving to In-Process Release Testing’
Presented by Scott Weiss, Director, Industrial Microbiology, Johnson & Johnson
• ‘Non-viable particle monitoring: Myths, mistakes and consequences’
Presented by Morgan Polen, SME, Cleanroom Contamination Control Expert, Microrite
• ‘Alternative endotoxin test methods for products exhibiting low endotoxin recovery’
Presented by Ren-Yo Forn, Scientific Director, Amgen
• ‘Paper Based Compliance versus Factual Contamination Control’
Presented by Ziva Abraham, President, Microrite

The updated brochure and the ‘preliminary attendee list.’ Can be found on the conference website ‘download centre’ visit

The conference is sponsored by: Associates of Cape Cod, bioMérieux, Lonza, Mettler Toledo, and Microcoat.

For sponsorship enquiries contact Alia Malick on +44 (0)20 7827 6164 or

For media enquiries, contact Simi Sapal on +44 (0) 20 7827 6162 or

SMi’s 4th Annual Pharmaceutical Microbiology West Coast Conference
Conference: June 17 – 18, 2021
Interactive Workshop: June 16, 2021
Virtual Conference: Online Access Only

— END—

About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at

Simi Sapal
SMi Group
email us here

Source: EIN Presswire

Long-Term Health Effects on Population Health Due to the Responses Taken to Contain COVID-19 Results From a Large Study

A study of data from a public health surveillance program by researchers from Saudi Arabia reveals an increase in health risk factors and chronic diseases

RIYADH, SAUDI ARABIA, May 28, 2021 / — A study of data from a public health surveillance program conducted by researchers from Saudi Arabia reveals an increase in health risk factors

The COVID-19 pandemic and the response to contain it placed several restrictions on healthcare services and our daily activities. Such disruptions can affect public health. In a recent study, researchers from the Sharik Association for Health Research, Saudi Arabia, have used results from a nationwide public health surveillance program to assess the health of the population. Their survey showed that there was an increase in risk factors for chronic noncommunicable diseases.

The global response to the COVID-19 pandemic was nearly unanimous, with many nations prioritizing the treatment of COVID-19 and implementing social distancing measures. However, these measures have had unintended consequences on public health. The singular focus given to the treatment of COVID-19 limited the ability of healthcare services to treat other medical conditions. Furthermore, studies have reported that the lockdown measures lowered physical activity levels and brought about changes in people’s diet and habits.

These disruptions in healthcare services and lifestyles can affect risk factors for chronic and noncommunicable diseases in individuals. In this regard, a group of researchers from the Chronic disease research group at the Sharik Association for Health Research, Saudi Arabia and other institutions have set out to examine the impact the responses to COVID-19 had on long term public health. "We wanted to investigate the consequences of COVID-19 responses on risk factor development, screening, treatment and management of noncommunicable diseases on the population health and bring to light the unintended consequences of the measures taken by countries to contain the pandemic," explains Dr. Nasser BinDhim, from the Sharik Association for Health Research and Principal Investigator of the study. Their findings have been published recently in the International Journal of Environmental Research and Public Health.

The researchers utilized preexisting health data collected by the nationwide Sharik Health Indicators Surveillance System (SHISS). This health surveillance system was initiated in 2020 to assess and monitor public health in Saudi Arabia. As part of the data collection process, a total of 30,134 participants, of whom 51.2% were female, were interviewed over the phone quarterly. The median age of the participants was 35.6 years and they were asked about their health conditions (intermediate risk factors and presence of noncommunicable chronic disease), dietary choices (fruit and vegetable consumption) and behavior (use of tobacco and physical activity levels). Based on the responses, the researchers were able to map out the prevalence of risk factors and chronic diseases throughout 2020.

The responses indicated significant changes in risk factors and the presence of chronic diseases after the first quarter of 2020. Following the lockdown period, the researchers noted lower levels of fruit and vegetable consumption and physical activity. They also observed an increase in e-cigarette use, hypercholesterolemia, hypertension and noncommunicable chronic diseases such as heart disease and diabetes.

The survey showed that the limitations placed to contain the pandemic increased health risk factors for chronic noncommunicable diseases. In light of the results from the survey, Ms. Nora A Althumiri suggests an alternative approach to handle the pandemic, "The results highlight the need for balance between managing the COVID-19 pandemic and population health in terms of the need to resume public health activities to prevent chronic diseases and their risk factors and monitor public health indicators regularly to avoid the second-order consequences of focusing on the pandemic only."

The findings also indicate the importance of health surveillance programs. Programs such as the SHISS are a key component to assess and monitor public health and gives researchers important information to formulate public health policies. Stressing its importance, Ms Mada Basyouni one of the researchers says, "The continuous monitoring of the population’s health risk factors, and early intervention, are recommended in order to prevent future increases in chronic diseases.”

Dr. Nasser BinDhim
Sharik Association for Health Research
Visit us on social media:

Source: EIN Presswire

Two Arc Manor published stories have been nominated for the highly prestigious Aurora Award in Canada.

The Oppenheimer Alternative

Galaxy’s Edge Magazine


THE OPPENHEIMER ALTERNATIVE, (novel) by Robert J. Sawyer & “Night Folk,” (short story) by Barb Galler-Smith, have been nominated for the 2021 Aurora Awards.

ROCKVILLE, MARYLAND, USA, May 28, 2021 / — THE OPPENHEIMER ALTERNATIVE, written by Robert J. Sawyer and published in the Untied States by CAEZIK SF & Fantasy (an imprint of Arc Manor), has been nominated in the best novel of the year category for the 2021 Aurora Awards in Canada.

Meticulously researched by one of the top authors in science fiction, THE OPPENHEIMER ALTERNATIVE retells the story of the Manhattan Project with a new twist that raises a whole other possible future—not only related to the war, but also humanity itself. Replete with historical characters and grounded science, this a must read for fans of hard science fiction and alternative history.

“Night Folk,” a charming and moving short story written by Barb Galler-Smith, was published in the forty-seventh issue of GALAXY’S EDGE magazine (also owned by Arc Manor). The story puts a new twist on supernatural creatures of the night and those who hunt them.

Arc Manor’s CAEZIK SF & Fantasy imprint recently brought us Robert A. Heinlein’s last published novel, THE PURSUIT OF THE PANKERA, based on a rediscovered manuscript. They are also publishing POWER CHALLENGES, the final novel written by six-time Hugo winner Ben Bova.

Other hardcover titles forthcoming from CAEZIK SF & Fantasy include REBOOTS: THE UNDEAD CAN DANCE by Mercedes Lackey and Cody Martin, SOULMATES by Mike Resnick and Lezli Robyn, and a science fiction romance anthology edited by Cat Rambo and Jennifer Brozek titled THE REINVENTED HEART, which includes stories written by noted female authors in the field, such such as Jane Yolen, Premee Mohamed, Seanan McGuire, and Naomi Kritzer.

The CAEZIK SF & Fantasy imprint also recently launched CAEZIK Notables, a series of speculative fiction books marking important milestones in science fiction or fantasy. Each book in the series has a new introduction. Iconic titles published, or scheduled to be published, include FRIDAY and DOUBLE STAR by Robert A. Heinlein, THE LONG TOMORROW by Leigh Brackett, MIDNIGHT AT THE WELL OF SOULS by Jack L. Chalker, SIMULACRON-3 and DARK UNIVERSE by Daniel F. Galouye, BOLO: ANNALS OF THE DINOCHROME BRIGADE by Keith Laumer, and THE WARLOCK IN SPITE OF HIMSELF by Christopher Stasheff. More titles are expected to be added to the series.

Shahid Mahmud
Arc Manor
+1 240-645-2214
email us here

Source: EIN Presswire

Fourier Intelligence awarded triple top awards at the 84th China International Medical Equipment Spring Expo

Fourier Intelligence’s RehabHub™

Fourier Intelligence’s RehabHub™

Alex GU, Founder, Group CEO, Fourier Intelligence.

Alex GU, Founder, Group CEO, Fourier Intelligence.

Zen Koh, Co-Founder, Group Deputy CEO, Fourier Intelligence.

Zen Koh, Co-Founder, Group Deputy CEO, Fourier Intelligence.

Fourier Intelligence’s ArmMotus™ M2 Pro is awarded the  “Most Innovative Rehabilitation Robotic Award” and the “Outstanding Industrial Design Award” at CMEF

Fourier Intelligence’s ArmMotus™ M2 Pro is awarded the “Most Innovative Rehabilitation Robotic Award” and the “Outstanding Industrial Design Award” at CMEF

Fourier Intelligence’s RehabHub™ - Centralised Management System and RehaCloud

Fourier Intelligence’s RehabHub™ – Centralised Management System and RehaCloud

Tech unicorn Fourier Intelligence is awarded the prestigious “Top Leading Rehabilitation Technology Enterprise Award” at the 84th CMEF

The RehabHub™ is an integrated and comprehensive rehabilitation platform, utilising 5G, AI, and haptic technology, that makes rehabilitation services affordable and quantifiable.”

— Zen KOH

SHANGHAI, CHINA, May 28, 2021 / — Fourier Intelligence, a global rehabilitation technology leader, has been awarded the prestigious “Top Leading Rehabilitation Technology Enterprise Award” at the 84th China International Medical Equipment (CMEF) Spring Expo. Beating some of the best entries, Fourier Intelligence’s newly revamped ArmMotus™ M2 Pro snatched two coveted awards: the “Most Innovative Rehabilitation Robotic Award” and the “Outstanding Industrial Design Award” at the annual top medical equipment event.

“We are not just a medical device manufacturing company,” Mr. Alex GU, Founder, Group CEO of Fourier Intelligence, says. “Our core competency is our ability to integrate sensors, haptic technology, motion control, Artificial Intelligence (AI), and 5G optimally into the RehabHub™ concept, which revolutionalised how technologies are being used in the clinical settings. As one of the world-leading companies in rehabilitation robotics, Fourier Intelligence has successfully installed thousands of devices in over 54 countries, benefiting millions of patients.”

Recognising Fourier Intelligence’s trailblazing and revolutionary global RehabHub™ concept, CMEF awarded Fourier Intelligence with the prestigious “Top Leading Rehabilitation Technology Enterprise Award.”

“The RehabHub™ is an integrated and comprehensive rehabilitation platform, utilising 5G, AI, and haptic technology, that makes rehabilitation services affordable and quantifiable,” Mr. Zen KOH, Co-Founder, Group Deputy CEO of Fourier Intelligence, says. “These awards are strong votes of confidence and recognition of our efforts in developing medical technologies to improves patients’ clinical recovery. We will continue to innovate and chart the course.”

The award-winning ArmMotus™ M2 Pro is an upper extremity rehabilitation robot equipped with advanced haptic force feedback powered by high-performance motors. It can deliver a highly immersive and interactive gamified functional training environment that motivates the users to perform self-initiated functional movements in high repetitions.

The highly innovative system provides an assist-as-needed feature that seamlessly supports the user through challenging task-oriented training. The integrated AI system generates a patient-specific training program for clinicians to enhance users’ progressive clinical recovery further. With machine learning techniques, gamification and remote monitoring capabilities, ArmMotus™ M2 Pro will enable health professionals to provide a personalised cognitive rehabilitation therapy.

About Fourier Intelligence
Fourier Intelligence is a technology-driven company, infusing creativity into the development of exoskeleton and rehabilitation robotics since 2015. Together with researchers, therapists, and patients, Fourier aims to excel in developing and redefining rehabilitation robotics solutions with inter-connectable intelligent robotics technology by elevating user experience with an intuitive, easy-to-use system to enhance the lives of both patients and therapists.

More information is available at:

About RehabHub™
The RehabHub™ concept is a revolutionary approach that disrupts the medical rehabilitation field. It addresses the challenges of severe limitations of ‘manpower’, ‘financial resource’, and ‘space’ plaguing the rehab industry and profession. Fourier Intelligence developed this concept to incorporate affordable, highly efficient, and space-saving medical robotics to ensure patients will no longer be denied optimum treatments due to a lack of resources.

More information is available at:

About CMEF:
The China International Medical Equipment Fair (CMEF) is a leading medical equipment exhibition that brings together international medical equipment brands to connect with medical equipment distributors, resellers, manufacturers, doctors, regulators and government agencies.

More information is available at:

Sarah Lim
Fourier Intelligence
+65 6911 6651
Visit us on social media:


Source: EIN Presswire

Digital Belly Fat Scanner "Bello" App Version 2.0 is Here – Here's What to Expect

Digital Belly Fat Scanner "Bello" with App Version 2.0

Digital Belly Fat Scanner “Bello” with App Version 2.0

Olive Healthcare is set to release ‘Bello’ app v2.0, bringing a variety of new features to improve metabolic health and manage abdominal fat more effectively.

SEOUL, GYEONGGI-DO, SOUTH KOREA, May 28, 2021 / — [Digital Belly Fat Scanner "Bello" App Version 2.0 is Coming – Here's What to Expect]

A South Korean biotech startup, Olive Healthcare Inc., is set to release ‘Bello’ app v2.0, bringing a variety of new features to help its users improve metabolic health and manage abdominal fat more effectively. The app is complementary to the company’s digital belly fat scanner, Bello, and will be available to download on both iOS and Android devices on May 31, 2021.

As the world’s first portable digital belly fat scanner, Bello uses its patented near-infrared technology to provide an accurate measurement of abdominal subcutaneous and visceral fat within 3 seconds anytime, anywhere. Visceral fat is a key indicator of metabolic syndrome, making it crucial to track for the prevention of metabolic diseases like diabetes and high blood pressure. Based on one’s health status, Bello also provides a recommended guide for nutrition and fitness activities through the ‘Bello’ app. People can now easily track and manage abdominal fat to maintain a healthy life and reduce the risk of obesity and chronic diseases.

New features on this app update:
– Quick scan process: Scan and get personalized results in just 3 seconds. Enjoy our upgraded, intuitive scan results screen.
– Weekly and monthly graph and chart: Track and manage your data visually. Scan yourself consistently to view your overall metabolic health trends
– Improved Metabolic Health Index (MHI): See where you lie within your MHI group range. Gauge and manage your health more precisely.
– Reminders based on personal goals: Choose your preferred reminder settings to scan yourself and update your physical information regularly. Use Bello more consistently to better manage your health and develop health lifestyle habits.
– Scan point system: Track your weekly and monthly scan records on the Bello everyday tab. Earn points for scanning yourself and updating your physical information.
– Membership levels and benefits: Manage your health consistently to earn points and level up! Unlock special benefits such as exporting your personal health data.
– Diet management based on activity level: View your remaining calories, calculated from your Basal Metabolic Rate and daily exercise and diet. Track and manage your diet and exercise plan.
– Customizable main page: Edit the Highlights cards on the main page based on your needs and preferences. Optimize your Bello app experience.
– Bello inquiry email: Bello is always with you. For assistance, go to the Browse tab and click on Email us!

With major overhauls in its app design, flow, and features, ‘Bello’ app v.2.0 is expected to streamline and personalize the Bello scanning and data tracking experience. This release emphasizes the importance of a consistent health routine, providing consistent Bello users with special benefits and more personalized health recommendations.

This brings in much anticipation for the future of Bello, which has already been widely recognized in the tech industry this past year. Bello was selected as the CES 2020 Innovation awards honoree and winning the iF 2020 Design Award, followed by a groundbreakingly successful launch on Indiegogo. Bello raised over $300K from 1,573 backers during its campaign period, making it into the top 1% of all Indiegogo campaigns.

Since then, Bello has entered the global retail market and has been recognized for its rapid growth within the space. Bello can be purchased on its online mall,, and Amazon.

Download the app on May 31, 2021:

Olive Healthcare Inc. is a startup providing readily accessible healthcare services and helping people make better choices for a healthier lifestyle. We aim to position ourselves as a leading healthcare company by leveraging non-radiative & non-invasive NIR (Near-infrared) technology, artificial intelligence algorithm, and big data processing for personalized service. Following the release of our digital belly fat scanner and main product, Bello, we plan to release a subsequent model for measuring both belly and body fat, along with a fitness tracking device and a breast cancer diagnostic device for hospitals.

PR contact:
Bello website:
Bello Amazon Listing:

Jinwook You
+82 10-3905-9933
email us here
Visit us on social media:

Source: EIN Presswire